Cost-effective management of diabetes mellitus

Ethnicity and Disease

Volumn 16, Issue SUPPL. 2, 2006, Pages

  Motala, Ayesha A ^a   Pirie, Fraser J ^a   Rauff, Sophia ^a   Bacus, Hajira B ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Cost effective management; Type 2 diabetes mellitus

Indexed keywords

BIGUANIDE; INSULIN; SULFONYLUREA; ANTIDIABETIC AGENT;

BLOOD PRESSURE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; RISK FACTOR; WEIGHT CONTROL; WORLD HEALTH ORGANIZATION; COST BENEFIT ANALYSIS; DISEASE MANAGEMENT; ECONOMICS; HEALTH CARE COST; PATHOPHYSIOLOGY;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 33746035722     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. World Health Organization Expert Committee. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28(1):S37-S42.
3. International Diabetes Federation. National diabetes fact sheet. May 2005. Available at: http://www.idf.org. Last accessed: May 9, 2005.
4. American Diabetes Association. Statistics. Available at: http://www.diabetes.org. Last accessed: May 8, 2005.
5. American Diabetes Association. Standards of medical cate in diabetes. Diabetes Care. 2005;28(1):S4-S36.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
8. Ohkubo Y, Kishikawa H, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a tandomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
9. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
10. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
11. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
12. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
13. Gaede P, Pederson O. Intensive integrated therapy of type 2 diabetes. Implications for long-tetm prognosis. Diabetes. 2004;53(3):S39-S47.
14. Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin N Am. 2005;34:77-98.
15. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333-1346.
16. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431.
17. Bays H, Mandarino L, De Fronzo R. Role of adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferators-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89(2):463-478.
18. Krentz AJ, Bailey CJ. Oral anti-diabetic drugs. Current role in type 2 diaberes mellitus. Drugs. 2005;65(3):385-411.
19. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150-1156.
20. Clark PM, Gray AM, Briggs A, Steven RJ, Mathews DR, Holman RR. On behalf of the UK Prospective Diabetes Study (UKPDS). Cost-utility analysis of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005;48:868-877.